This virtual event will bring together expert regulators, academics and drug industry scientists to define the challenges and share the latest research breakthroughs to help formulators make the decisions that enable them overcome their bioavailability challenge.
Dr. Vivian Bi, technical director of solubilization and contract research, Ashland Specialty Ingredients, will present "Overcoming the Challenges of Poorly Soluble Compounds through Rational Formulation Design." As poorly soluble compounds have become one of the major challenges in drug development, solubilization technologies, such as solid dispersions, complexation, size reduction and lipid-based formulations, have significantly advanced in recent years. The selection of the right solubilization technology not only requires a thorough understanding of the API, but also requires extensive knowledge of excipients and processes.
Following her presentation, a discussion will cover:
● How to choose suitable formulation technologies for poorly soluble APIs: Conventional vs. unconventional formulation approaches
● Considerations when selecting an excipient to maximize formulation performance: Physicochemical properties, processability, regulatory considerations and beyond
● When and how the solubilization process impacts formulation selection: Understanding advantages and limitations of different process technologies
● The art of formulating poorly soluble compounds: Case studies
Click here to register for Bioavailability Challenge.
Dr. Vivian Bi held various positions with Pfizer, Vertex and AstraZeneca before joining Ashland. As associate principal scientist at AstraZeneca, she was the head formulator of Medicine Evaluation in the US/UK region and led the global formulation network. Her research interests are oral and parenteral drug delivery systems. She has published more than 50 research papers, abstracts and patents. She also serves as a reviewer for research journals such as Pharmaceutical Research and Journal of Pharmaceutical Sciences. Bi holds a bachelor's degree from Shenyang Pharmaceutical University in China, and a doctorate in Pharmaceutical Science from Meijo University in Japan.